AST-201 is under clinical development by EpiThany and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AST-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AST-201 overview
AST-201 is under investigation for the treatment of patients with ovarian cancer. The vaccine candidate is administered through the intradermal route. The therapeutic candidate was a plasmid DNA vaccine containing mammalian expression vector pUMVC3, encoding epitopes of human insulin-like growth factor-binding protein 2 (hIGFBP-2) with potential immunostimulating and anti-neoplastic activities. It was also under development for the treatment of stage III-IV ovarian cancer, peritoneal cancer and fallopian tube cancer as a first line therapy.
EpiThany overview
EpiThany is a tumor vaccine company that focuses on the development of novel vaccines for the treatment of cancer. The company conducts clinical programs to develop a multi-antigen vaccine for various therapeutic areas such as breast cancer, ovarian cancer, colorectal cancer and others. It also develops anti-cancer immunotherapy for robust tumor-targeted T-cell immunity. It’s technology enables the targeting of a multitude of tumor antigens across various cancers driving Th1-selective immune responses. EpiThany is headquartered in Seattle, Washington, the US.
For a complete picture of AST-201’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
